These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17204703)

  • 1. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
    de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Krenning EP; de Jong M
    J Nucl Med; 2007 Jan; 48(1):88-93. PubMed ID: 17204703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
    Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
    J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14).
    Reubi JC; Wenger S; Schmuckli-Maurer J; Schaer JC; Gugger M
    Clin Cancer Res; 2002 Apr; 8(4):1139-46. PubMed ID: 11948125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
    Markwalder R; Reubi JC
    Cancer Res; 1999 Mar; 59(5):1152-9. PubMed ID: 10070977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
    Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
    Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications.
    Fleischmann A; Waser B; Reubi JC
    Endocr Relat Cancer; 2009 Jun; 16(2):623-33. PubMed ID: 19478282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
    J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.
    Chang GT; Jhamai M; van Weerden WM; Jenster G; Brinkmann AO
    Endocr Relat Cancer; 2004 Dec; 11(4):815-22. PubMed ID: 15613454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of seven new human prostate tumor xenograft models and their histopathological characterization.
    van Weerden WM; de Ridder CM; Verdaasdonk CL; Romijn JC; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Am J Pathol; 1996 Sep; 149(3):1055-62. PubMed ID: 8780407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
    Maina T; Nock BA; Zhang H; Nikolopoulou A; Waser B; Reubi JC; Maecke HR
    J Nucl Med; 2005 May; 46(5):823-30. PubMed ID: 15872357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Cai RZ; Baker B; Hammann BD; Armatis P; Kanashiro CA
    Eur J Cancer; 2005 Nov; 41(17):2735-44. PubMed ID: 16291086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
    Lin KS; Luu A; Baidoo KE; Hashemzadeh-Gargari H; Chen MK; Pili R; Pomper M; Carducci M; Wagner HN
    Bioconjug Chem; 2004; 15(6):1416-23. PubMed ID: 15546210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
    Zhou J; Chen J; Mokotoff M; Zhong R; Shultz LD; Ball ED
    Clin Cancer Res; 2003 Oct; 9(13):4953-60. PubMed ID: 14581370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.